PT - JOURNAL ARTICLE AU - Mireia Crispin-Ortuzar AU - Ramona Woitek AU - Elizabeth Moore AU - Marika Reinius AU - Lucian Beer AU - Vlad Bura AU - Leonardo Rundo AU - Cathal McCague AU - Stephan Ursprung AU - Lorena Escudero Sanchez AU - Paula Martin-Gonzalez AU - Florent Mouliere AU - Dineika Chandrananda AU - James Morris AU - Teodora Goranova AU - Anna M. Piskorz AU - Naveena Singh AU - Anju Sahdev AU - Roxana Pintican AU - Marta Zerunian AU - Helen Addley AU - Mercedes Jimenez-Linan AU - Florian Markowetz AU - Evis Sala AU - James D. Brenton TI - Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer AID - 10.1101/2021.07.22.21260982 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.22.21260982 4099 - http://medrxiv.org/content/early/2021/07/23/2021.07.22.21260982.short 4100 - http://medrxiv.org/content/early/2021/07/23/2021.07.22.21260982.full AB - High grade serous ovarian cancer (HGSOC) is a highly heterogeneous disease that often presents at an advanced, metastatic state. The multi-scale complexity of HGSOC is a major obstacle to measuring response to neoadjuvant chemotherapy (NACT) and understanding its determinants. Here we propose a radiogenomic framework integrating clinical, radiomic, and blood-based biomarkers to measure and predict the response of HGSOC patients to NACT, showing how quantitative imaging data can serve as the backbone of multi-scale data integration. We developed and validated our approach in two independent highly-annotated multi-omic multi-lesion data sets. In a discovery cohort (n=72) we found that different tumour sites present distinct response patterns, and identified volumetric response assessment as a better predictor of overall survival (OS) than RECIST 1.1 status. We trained an ensemble machine learning approach to predict tumour volume response to NACT from data obtained prior to treatment, and validated the model in an internal hold-out cohort (n=20) and an independent external patient cohort (n=42). Benchmarking integrated models against models built on single data types highlighted the importance of comprehensive patient characterisation. Our study sets the foundation for developing new clinical trials of NACT in HGSOC.Competing Interest StatementFMo, DC, JMo, AP and JB are inventors of the patent 'Enhanced detection of target DNA by fragment size analysis' (WO/2020/094775). JB is an inventor of the patent 'TAm-Seq v2 method for ctDNA estimation'. TG is an employee of and owns shares from AstraZeneca. FMa and JB are founders and directors of Tailor Bio. JB owns share from Inivata and Tailor Bio, and has received honoraria from AstraZeneca and GSK. ES is co-founder and shareholder of Lucida Medical Ltd. LR has received consulting fees from Lucida Medical Ltd.Clinical TrialREC reference number: 08/H0306/61Funding StatementThis work was partially supported by The Mark Foundation for Cancer Research and Cancer Research UK Cambridge Centre [C9685/A25177], the Wellcome Trust Innovator Award [RG98755] and the CRUK National Cancer Imaging Translational Accelerator (NCITA) [C42780/A27066]. Additional support was also provided by the National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Microsoft Radiomics was provided to the Addenbrooke's Hospital (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK) by the Microsoft InnerEye project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients within the main data set were treated at Cambridge University Hospitals NHS Foundation Trust between 2009 and 2020 and were recruited into a prospective clinical study approved by the local research ethics committee (REC reference numbers: 08/H0306/61). All patients within the Barts data set were treated at Barts Health NHS Trust between 2009 and 2018 and recruited into prospective clinical study approved by the local research ethics committee (IRAS reference numbers: 243824).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code and data can be found at https://github.com/micrisor/OvarianIntegration https://github.com/micrisor/OvarianIntegration